MavriX Bio MVX-220 Update
MavriX Bio’s gene therapy MVX-220 receives FDA Fast Track designation, with its Phase 1/2 ASCEND-AS trial now listed and a community webinar set for October 9.
More Than a Seat at the Table: FAST’s Role in Shaping the Future of Angelman Syndrome at ASGCT 2025
FAST attended this year’s ASGCT conference, where Angelman syndrome was featured in 10 scientific presentations and multiple talks—proof the community is helping drive the future of gene and cell therapy.
MavriX Bio Announces FDA Clearance of IND Application to Initiate First-in-Human Study of Gene Therapy for Angelman Syndrome
The FDA has cleared MavriX Bio’s IND application for MVX-220, an investigational AAV gene therapy for Angelman syndrome.
FAST Italy Hosts Its First Scientific Symposium on Angelman Syndrome
FAST Italy’s first-ever Scientific Symposium drew over 100 attendees and unveiled two new biotech companies, MavriX Bio and CourageAS Bio, advancing gene therapies for Angelman syndrome.